CRA consultants assessed whether disputed representations of bioequivalence significantly affected sales of the branded product. The evaluation included consideration of distribution channels, purchase timing, and the effect of payor control mechanisms on product uptake and sales. The case ultimately resulted in a settlement.
AI in Health Care: Case Law and Enforcement Trends
Their discussion explores pressing issues surrounding artificial intelligence in healthcare, including antitrust concerns, patient-facing applications, claims...